Biorestorative (BRTX) news
Recent news
BioRestorative Therapies: conducting review of the documentation, sourcing, regulatory status associated with suspended products - SEC filing
BioRestorative Therapies, Inc. (BRTX) has disclosed in its most recent SEC filing that the company is conducting a comprehensive review of the documentation, sourcing, and regulatory status of its suspended products. The filing, submitted on March 28, 2025, as part of the company’s annual report…
AInvest Wire · Aug 14, 2026BioRestorative Therapies: suspends all orders, shipments of Exocr, BioX biocosmetic product lines effective immediately, on Aug 7 - SEC filing
BioRestorative Therapies, Inc. (NASDAQ: BRTX) has announced the immediate suspension of all orders and shipments for its Exocr and BioX biocosmetic product lines, effective August 7, 2026, as disclosed in a recent SEC filing. This decision follows a strategic reassessment of the company’s…
AInvest Wire · Aug 14, 2026BioRestorative Therapies - appoints Katharyn Field as interim CFO, treasurer, and secretary effective July 13, 2026 - SEC filing
BioRestorative Therapies Inc. (NYSE: BRTX) has announced the appointment of Katharyn Field as interim Chief Financial Officer, Treasurer, and Secretary, effective July 13, 2026[1]. The appointment was disclosed in a recent filing with the U.S. Securities and Exchange Commission. Field brings…
AInvest Wire · Jul 16, 2026BioRestorative Therapies - Lance Alstodt resigns as president, CEO, chairman and all other positions effective July 13, 2026 - SEC filing
Lance Alstodt has resigned from all positions at BioRestorative Therapies, Inc., including president, chief executive officer, and chairman of the board, effective July 13, 2026, according to a recent SEC filing [1]. The resignation marks a significant leadership transition for the company, which…
AInvest Wire · Jul 16, 2026Kaos Capital buys 4.9% stake in BioRestorative Therapies
Kaos Capital has acquired a 4.9% stake in BioRestorative Therapies, Inc. (NASDAQ: BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products. The investment aligns with the company’s recent operational and financial milestones, including the…
AInvest Wire · May 27, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.